# A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

> **NCT05380947** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 13 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1810631 - trial formulation 1 (TF1)
- **DRUG:** BI 1810631 - new formulation (NF)
- **DRUG:** Rabeprazole sodium

## Key facts

- **NCT ID:** NCT05380947
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-23
- **Primary completion:** 2022-09-13
- **Final completion:** 2022-09-13
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05380947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05380947, "A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05380947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*